Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1867096 · FYE Dec 31 · Prices AT CLOSE 2026-08-21 (USD) Last $8.70 · Day +1.16% · Mkt cap $1.6B · 1Y +14.6% · Off 52W high −13.7% · Vol (1Y) 53.4% Price2023-08-21 → 2026-08-21 XERS close: $2.39 on 2023-08-21 to $8.70 on 2026-08-21. Split-adj closes · 240 of 2,048 · price returnⓘ At a glance | Short interest5.1% of sh out | | Days to cover6.8d | | 13F net flow (QoQ)+3.24% | | Top-10 13F concentration49.6% | | Next report (est.)2026-11-05 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$335.4M | | Earnings (TTM)-$17.2M | | Net margin0.2% | | ROIC19.6% | | Debt / equity16.10× | | Total debt / EBITDA8.41× | | Sales growth 3Y38.3% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+10.8% | | 1Y+14.6% | | 3Y+264.0% | | 5Y+225.8% | | Since incept. (ann.)−9.8% |
Total return · from 2018-06-21ⓘ Risk | Ann. volatility (1Y)53.4% | | Ann. volatility (3Y)60.8% | | Sharpe (1Y)0.54 | | Sharpe (3Y)1.02 | | Max drawdown (1Y)−46.6% | | Max drawdown (3Y)−47.2% | | Beta (3Y vs SPY)0.61 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 12.9M | $75M | 7.51% | +2.4% | | D. E. Shaw & Co., Inc. | 7.8M | $45M | 4.52% | +2.8% | | VANGUARD CAPITAL MANAGEMENT LLC | 7.0M | $40M | 4.05% | new | | STATE STREET CORP | 4.7M | $27M | 2.70% | +13.1% | | GEODE CAPITAL MANAGEMENT, LLC | 4.3M | $25M | 2.49% | +0.3% | | Qube Research & Technologies Ltd | 4.1M | $24M | 2.39% | +17.6% | | Rosalind Advisors, Inc. | 3.2M | $19M | 1.87% | +53.0% | | Nuveen, LLC | 2.9M | $17M | 1.69% | +3.9% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-06 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-06 | −$0.18 | — | $92.1M | +28.7% | | 2026-03-31 | 2026-05-07 | $0.01 | — | $83.1M | +38.3% | | 2025-12-31 | 2026-03-02 | — | — | $85.8M | +42.8% | | 2025-09-30 | 2025-11-06 | $0.00 | — | $74.4M | +37.1% |
As-reported XBRL · next 2026-11-05 est.ⓘ Segment mixFY2025 (ended Dec 2025) Product 49% · Recorlev 24% · Gvoke 16% · Keveyis 8% · Royalty Contract And Other Revenue 2% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
